ERBB2 and breast carcinoma: Evaluate the clinical significance of the PRO Onc assay and assess the efficacy of HER2‐targeted therapy (trastuzumab/pertuzumab) in patients with HER2‐negative breast cancer identified as having HER2 overexpression/activation by the PRO Onc Assay.